This is an old revision of this page, as edited by Boghog (talk | contribs) at 07:58, 27 December 2024 (created drug stub). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 07:58, 27 December 2024 by Boghog (talk | contribs) (created drug stub)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Pharmaceutical compound
Clinical data | |
---|---|
Other names | ALK-001, KL-49 |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C20H30O |
Molar mass | 286.459 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Gildeuretinol is an investigational new drug being developed by Alkeus Pharmaceuticals for the treatment of retinal diseases, particularly Stargardt disease and geographic atrophy secondary to age-related macular degeneration (AMD). Stargardt disease is caused by a defect in the ABCA4 gene that clears toxic byproducts resulting from the dimerization of vitamin A. Gildeuretinol is a deuterated derivative of Vitamin A that is designed to reduce the dimerization of vitamin A without affecting the visual cycle.
Gildeuretinol has received breakthrough therapy and orphan drug designations from the U.S. Food and Drug Administration.
References
- Zaydon YA, Tsang SH (July 2024). "The ABCs of Stargardt disease: the latest advances in precision medicine". Cell & Bioscience. 14 (1): 98. doi:10.1186/s13578-024-01272-y. PMC 11282698. PMID 39060921.
- Fitch J (22 November 2024). "Gildeuretinol for Stargardt disease receives Rare Pediatric Disease, Fast Track Designations". Contemporary Pediatrics.
This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |